# Sintilimab plus a bevacizumab biosimilar (IBI305) versus sorafenib in unresectable hepatocellular carcinoma (ORIENT-32): a randomised, open-label, phase 2–3 study

**Type:** Papers  
**Canonical URL:** https://scholariq.org/papers/sintilimab-plus-a-bevacizumab-biosimilar-ibi305-versus-sorafenib-in-unresectable/

## Facts

| Field | Value |
| --- | --- |
| Author Names | Zhenggang Ren,Jianming Xu,Yuxian Bai,Aibing Xu,Shundong Cang,Chengyou Du,Qiu Li,Yinying Lu,Yajin Chen,Yabing Guo,Zhendong Chen,Baorui Liu,Weidong Jia,Jian Wu,Junye Wang,Guoliang Shao,Bixiang Zhang,Yunfeng Shan,Zhiqiang Meng,Jianbing Wu,Shanzhi Gu,Wei Yang,Chao Liu,Xuetao Shi,Zhenyuan Gao,Tao Yin,Jiuwei Cui,Ming Huang,Bao-Cai Xing,Yilei Mao,Gao‐Jun Teng,Yanru Qin,Jinhai Wang,Feng Xia,Guowen Yin,Yong Yang,Mingxia Chen,Yan Wang,Hui Zhou,Jia Fan |
| Citations | 1,135 |
| DOI | 10.1016/s1470-2045(21)00252-7 |
| Fields | Medicine |
| Open Access | false |
| OA Status | closed |
| OpenAlex ID | https://openalex.org/W3166753505 |
| PMID | 34143971 |
| Type | article |
| Year | 2021 |

## Paper authors

- [Shundong Cang](https://scholariq.org/researchers/shundong-cang/)

## Paper journal

- [The Lancet Oncology](https://scholariq.org/journals/the-lancet-oncology/)

## Paper primary topic

- [Hepatocellular Carcinoma Treatment and Prognosis](https://scholariq.org/topics/hepatocellular-carcinoma-treatment-and-prognosis/)

## Paper topics

- [Hepatocellular Carcinoma Treatment and Prognosis](https://scholariq.org/topics/hepatocellular-carcinoma-treatment-and-prognosis/)
- [Cancer Immunotherapy and Biomarkers](https://scholariq.org/topics/cancer-immunotherapy-and-biomarkers/)
- [Colorectal Cancer Treatments and Studies](https://scholariq.org/topics/colorectal-cancer-treatments-and-studies/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.